Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Spironolactone-associated digoxin radioimmunoassay interference. [/sup 3/H, /sup 125/I tracer techniques]

Journal Article · · Clin. Chem.; (United States)
OSTI ID:6368496
Apparent digoxin was measured in the serum of 21 patients receiving spironolactone and in 21 controls, by use of a sequential-saturation /sup 3/H-radioimmunoassay (RIA) and an equilibrium /sup 125/I-RIA. No patient had been given digoxin for at least four weeks. ''Digoxin'' values in the former group were significantly (p < 0.05) higher than in the control group, and often were in or near the ''therapeutic'' range by the equilibrium /sup 125/I-RIA, but not by the sequential-saturation /sup 3/H-RIA. Canrenone (a major active metabolite of spironolactone) in the serum of the former group was measured by a newly developed liquid-chromatographic technique and correlated (r = 0.73) with ''digoxin'' concentrations by the /sup 125/I-RIA. However, external addition of canrenone to control serum in comparable concentrations did not cause appreciable ''digoxin'' values by the /sup 125/I-RIA. These findings suggest that other metabolites of spironolactone are responsible for the assay interference, the degree of which appears to depend on antibody specificity. Therefore, assay specificity should be established in clinical laboratories by using digoxin-free serum from patients ingesting spironolactone, and not by using spironolactone- or canrenone-fortified digoxin-free serum.
Research Organization:
Univ. of California, San Francisco
OSTI ID:
6368496
Journal Information:
Clin. Chem.; (United States), Journal Name: Clin. Chem.; (United States) Vol. 25:1; ISSN CLCHA
Country of Publication:
United States
Language:
English